Effect of estrogen on the resistance and compliance of pulmonary vasculature in PAH. (a) The placebo-treated control group (CTL_P), (b) the estrogen-treated control group (CTL_E), (c) the placebo-treated SuHx group (SuHx_P), (d) the estrogen-treated SuHx group (SuHx_E), (e) Resistance (Z0), (f) Characteristic impedance (ZC), (g) Global compliance, and (h) Pulse wave reflection index. * P<;0.05 vs. Control, # P<0.05 vs. Placebo.”